Table of Contents
Healthcare Company Financing Enters a New Phase: Shifting from “Financing Amount” to “Capital Efficiency”
In the past, when discussing financing in the healthcare industry, “how much money was raised” was often the most straightforward metric.
A larger financing amount typically meant that a company had secured more ample resources for development and could build a stronger financial reserve in a competitive market.
However, as the healthcare industry enters a development stage that places greater emphasis on commercialization, operational efficiency, and industrial synergy, solely pursuing the scale of financing has become increasingly inadequate to fully reflect a company’s capital value.
For companies in innovative drugs, medical devices, medical diagnostics, healthcare services, and health tech, the core question of financing is shifting from:
“How much money can we raise?”
to:
“What can this capital create for the company, and how long will it take to create it?”
This means that healthcare company financing is entering a new phase with a greater focus on Capital Efficiency.
Capital efficiency does not mean that companies must reduce their financing. Instead, it requires companies to answer three questions more clearly:
- Why do we need financing now?
- How will the capital be converted into company value after financing?
- What are the operational and industrial milestones for the next stage?
I. Financing Amount Does Not Equal Financing Value
For a healthcare company, the financing amount is only part of the transaction result.
What truly affects the long-term value of the company is whether the funds, once received, can drive the achievement of key milestones.
For example, after an innovative drug company completes a round of financing, the funds may be used to:
- Advance clinical trials;
- Complete key clinical data;
- Push for regulatory submission;
- Build a commercialization team;
- Expand production capacity;
- Promote licensing cooperation;
- Carry out the next stage of pipeline layout.
A medical device company, on the other hand, might use the financing proceeds for:
- Product R&D;
- Registration and certification;
- Clinical validation;
- Production line construction;
- Sales channel development;
- Overseas market expansion;
- Strategic M&A.
Therefore, even with the same CNY 100 million in financing, the value ultimately created by different companies can be completely different.
If the capital only extends the company’s cash burn period without significantly changing the product, revenue, technology assets, or industry position, then a larger financing amount does not necessarily mean higher capital efficiency.
Conversely, if a round of financing can help a company complete a key clinical milestone, obtain core registration qualifications, establish commercial revenue, or complete important industrial cooperation, then the capital’s contribution to the company’s value may be more significant.
Therefore, when formulating a financing plan, companies need to shift from a “financing amount mindset” to a “milestone mindset.”
II. What is Capital Efficiency for a Healthcare Company?
In the context of corporate financing, capital efficiency can be understood as:
The ability of a company to convert external capital into R&D progress, product commercialization, revenue growth, industrial synergy, and long-term corporate value.
It is not a single financial metric but a comprehensive judgment framework.
For healthcare companies, the following dimensions can be observed.
1. Does the Funding Correspond to Clear Strategic Goals?
Before financing, a company must first clarify the use of funds.
For example:
R&D-focused Company
Financing → Clinical Research → Key Data → Registration/Commercialization Milestone
Medical Device Company
Financing → Product R&D → Registration & Certification → Commercialization → Revenue Growth
Healthcare Service Company
Financing → Network Expansion → Service Capability Improvement → Single-store/Single-center Efficiency Improvement → Scaled Growth
Platform or Technology Company
Financing → Technology R&D → Productization → Customer Acquisition → Revenue Growth
If the use of funds cannot be linked to clear strategic goals, it is difficult for investors to judge what results the capital investment will produce.
Therefore, an effective financing plan should not only state “plan to raise X hundred million yuan in the next two years,” but also answer:
What specific milestones will this money help the company achieve?
III. Shifting from “Financing Amount” to “Milestone-Based Financing”
Healthcare companies are particularly well-suited to a milestone-driven financing approach.
The reason is that the value of healthcare companies often changes in stages with the completion of key milestones such as R&D, registration, clinical trials, and commercialization.
For example, an innovative drug company might go through:
Early Discovery → Preclinical → IND → Phase I → Phase II → Phase III → NDA/BLA → Commercialization
Different stages correspond to different risk levels, capital needs, and potential partners.
If a company raises funds far exceeding its current development needs in the early stages, although it can reduce short-term cash pressure, it may also bring problems such as valuation, equity dilution, and inefficient use of capital.
Therefore, a more important question is:
To what position should the current round of financing advance the company?
For example:
- From preclinical to IND;
- From Phase I to Phase II;
- Completing key clinical data;
- Completing product registration;
- Building a commercialization team;
- Achieving initial commercial revenue;
- Completing overseas market validation.
When the financing amount is linked to clear corporate milestones, the logic for using the capital becomes clearer.
IV. Capital Efficiency is Increasingly Related to Commercialization Capability
In the past, the capital story of healthcare companies might have revolved more around technology, pipelines, and R&D progress.
But for companies that have entered the commercialization stage, investors usually also need to pay attention to:
- Product revenue;
- Gross margin;
- Customer acquisition cost;
- Sales efficiency;
- Cash collection cycle;
- Market coverage;
- Product portfolio;
- Efficiency of the commercialization team.
This means that the company’s financing strategy also needs to change.
If a company already has mature products and commercialization capabilities, the focus of its financing story may no longer be just:
“What technology do we have?”
but rather:
“How can we use capital to expand our proven business model?”
For example, if a medical device company has completed the registration of its core product and has established stable sales in several hospitals, the next round of capital may be used to expand production capacity, channel coverage, product matrix, and overseas markets.
At this point, capital efficiency can be further reflected in:
New Capital → New Market Coverage → New Customers → New Revenue → Increased Company Value
This logic of capital use is usually easier to quantify and discuss than simply increasing cash reserves.
V. The Value of Industrial Capital and Financial Capital is Not the Same
There is another important change in healthcare company financing:
The financing source itself is becoming more important.
Traditional financing typically focuses on the scale of funding, valuation, and transaction terms.
But for healthcare companies, industrial investors may bring resources beyond capital, such as:
- Hospital and medical institution resources;
- Drug or device commercialization channels;
- Production and supply chain capabilities;
- Registration and compliance experience;
- Overseas market resources;
- BD cooperation opportunities;
- Upstream and downstream industrial synergy;
- Subsequent M&A opportunities.
Therefore, in the financing process, the company needs to consider not only:
“Who is willing to give me the most money?”
but also:
“Who can help me achieve the strategic goals of the next stage faster?”
This is also the important difference between strategic investors, industrial capital, and financial investors.
For some healthcare companies, the strategic value of an investor who can bring industrial synergy may not be reflected in the investment amount itself.
VI. Valuation is Not the Only Goal of Financing
During the financing process, companies usually pay close attention to valuation.
A higher valuation means less equity dilution, which is certainly an important transaction factor.
But if a company accepts an excessively large financing amount, excessively high performance commitments, or mismatched development goals in pursuit of a higher valuation, it may increase the company’s operational pressure later on.
Therefore, financing decisions need to consider simultaneously:
Financing Amount + Valuation + Dilution Ratio + Use of Funds + Future Milestones + Next Round Financing Space
For example, a company can ask:
- Is the current valuation matched with the company’s development stage?
- How long can this round of financing support business development?
- What milestones need to be reached for the next round of financing?
- Will the current financing cause unnecessary equity dilution?
- What resources beyond capital can the investor provide?
- Is the current transaction structure conducive to the company’s future financing?
From this perspective, financing is not an isolated capital transaction, but part of the company’s capital strategy.
VII. Financing Plans Should Be Upgraded from “Cash Needs” to “Capital Planning”
When many companies start financing, they first calculate:
“How much money do we need for the next 18 months?”
This is necessary, but not enough.
A more complete capital plan should include:
First Layer: Company Development Plan
What does the company hope to accomplish in the next 12-36 months?
For example:
- Product launch;
- Clinical milestones;
- Revenue growth;
- Entry into overseas markets;
- Capacity expansion;
- New product development;
- M&A integration.
Second Layer: Capital Needs
How much funding does each strategic goal require?
Third Layer: Financing Rhythm
Should these funds be raised all at once, or in stages?
Fourth Layer: Capital Sources
At different stages, should we look for:
- Financial investors;
- Industrial investors;
- Strategic partners;
- Overseas capital;
- M&A buyers.
Fifth Layer: Next Stage Capital Path
After this round of financing is completed, what is the company’s next step:
- A new round of financing;
- IPO;
- M&A;
- Licensing;
- Strategic cooperation;
- Equity sale?
When these questions are considered in the same capital plan, financing truly becomes part of the corporate strategy.
VIII. Capital Efficiency Also Means More Emphasis on “Post-Financing Company Value”
The completion of financing is not the end of capital work.
For the management team, what is more worthy of attention is the result of capital use after financing.
For example, a simple post-financing management framework can be established:
| Capital Input | Target Milestone | Measurement Metric |
|---|---|---|
| R&D Funds | Complete key R&D nodes | Clinical/Technical Progress |
| Registration Funds | Complete product registration | Registration Progress |
| Commercialization Funds | Expand market coverage | Revenue, number of customers |
| Production Funds | Expand production capacity | Capacity Utilization Rate |
| BD Funds | Establish industrial cooperation | Cooperation Projects |
| Overseas Funds | Expand international markets | Overseas revenue/cooperation |
In this way, the company can judge more clearly:
Whether the financing has truly been transformed into corporate development results.
IX. Financing Strategy Also Needs to Consider the Next Round of Capital Market Environment
A healthcare company’s capital planning cannot only consider the current round of financing.
After a round of financing is completed, the company will eventually still need to face the next stage of the capital market.
Therefore, the current round of financing should, as much as possible, help the company establish the necessary conditions for the next round of financing.
For example:
Early-stage Financing
The focus may be on technology validation, product development, and clinical progress.
↓
Growth-stage Financing
The focus may shift to registration, commercialization, and revenue growth.
↓
Mature-stage Financing
The focus may shift to scale, industrial integration, M&A, and international markets.
↓
Strategic Transactions
Value may be further realized through M&A, licensing, strategic cooperation, or the capital market.
Therefore, companies need to avoid viewing each round of financing as an isolated event, but should place it in a longer-term capital path.
X. How Can Healthcare Companies Improve Financing Capital Efficiency?
For companies preparing for financing, they can start from the following aspects.
1. Clarify the Purpose of Financing
Don’t just determine the financing amount, but determine:
Financing → Goal → Milestone
2. Match Funding with the Development Stage
The scale of financing should match the actual capital needs of the company for a period of time in the future.
3. Quantify the Use of Funds
As much as possible, link the use of funds to specific business indicators.
4. Design the Conditions for the Next Round of Financing in Advance
The company should think in advance:
After this round of financing is completed, what changes can prove that the company’s value has increased?
5. Don’t Just Look for Capital
For healthcare companies, industrial resources, BD capabilities, commercialization capabilities, and international resources may be equally important.
6. Place Financing within the Company’s Overall Capital Strategy
Financing, M&A, licensing, strategic cooperation, and future capital market arrangements should form a continuous capital path as much as possible.
Conclusion: The End Point of Financing is Not “Getting the Money,” but Completing the Next Stage of Value Creation
The healthcare industry is still a highly capital-dependent industry.
R&D, clinical trials, registration, production, commercialization, and international market expansion all require long-term capital support.
But against the backdrop of a constantly changing capital environment and corporate development stages, corporate financing needs to focus on more than just the financing amount.
A more important question is:
After capital enters the company, can it drive the achievement of key milestones and further create new corporate value?
Therefore, the financing strategy of healthcare companies is gradually shifting from “scale-oriented” to a more systematic capital efficiency-oriented approach.
For the management team, what is truly worth paying attention to in a round of financing is not just:
“How much money can we raise this time?”
but rather:
“Where will this capital take the company?”
If a company can clearly answer the use of funds, key milestones, industrial synergy, value enhancement, and the next-stage capital path, then financing is no longer just about solving cash needs, but can become an important tool to promote the company’s strategic development.
For investors and corporate management, this also means that future discussions on healthcare financing will increasingly shift from a single financing scale to the relationship between capital and corporate value creation.
T-Capital’s View
T-Capital focuses on capital transactions and strategic consulting in the healthcare field, providing services such as private financing, M&A and sale, licensing & BD, strategic cooperation, and cross-border transactions for healthcare companies.
In financing projects, companies need to comprehensively consider the development stage, capital needs, financing structure, investor type, industrial resources, and next-stage strategic goals, not just the current financing amount.
If your company is planning the next round of financing, it is recommended to first clarify three questions:
- What key business or R&D milestones does this round of capital need to drive?
- What type of investor can provide industrial value beyond capital?
- After this round of financing is completed, what is the company’s next-stage capital path?
Building a financing strategy around these three questions can help companies more systematically evaluate financing scale, investor selection, and transaction structure.